New Advances in Polycystic Liver Diseases

Abstract

Polycystic liver diseases (PLDs) include a heterogeneous group of congenital disorders inherited as dominant or recessive genetic traits; they are manifested alone or in association with polycystic kidney disease. Ductal plate malformation during embryogenesis and the loss of heterozygosity linked to second-hit mutations may promote the dilatation and/or development of a large number (> 20) of biliary cysts, which are the main cause of morbidity in these patients. Surgical procedures aimed to eliminate symptomatic cysts show short-term beneficial effects, but are not able to block the disease progression. Therefore, liver transplantation is the only curative option. Intense studies on the molecular mechanisms involved in the pathogenesis of PLDs have resulted in different clinical trials, some of them with promising outcomes. Here the authors summarize the key aspects of PLD etiology, pathogenesis, and therapy, highlighting the most recent advances and future research directions.

Keywords

polycystic liver diseases - hepatic cystogenesis - etiology - pathogenesis - therapy

^* Both authors contributed equally to this work.

• References

• 1 Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013; 10 (2) 101-108
• 2 Perugorria MJ, Masyuk TV, Marin JJ , et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol 2014; 11 (12) 750-761
• 3 Banales JM, Munoz-Garrido P, Bujanda L. Somatic second-hit mutations leads to polycystic liver diseases. World J Gastroenterol 2013; 19 (1) 141-143
• 4 Wills ES, Roepman R, Drenth JP. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 2014; 20 (5) 261-270
• 5 Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 2003; 33 (3) 345-347
• 6 Li A, Davila S, Furu L , et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet 2003; 72 (3) 691-703
• 7 Davila S, Furu L, Gharavi AG , et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 2004; 36 (6) 575-577
• 8 Cnossen WR, te Morsche RH, Hoischen A , et al. Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci U S A 2014; 111 (14) 5343-5348
• 9 The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14.  kb transcript and lies within a duplicated region on chromosome 16. Cell 1994; 77 (6) 881-894
• 10 Mochizuki T, Wu G, Hayashi T , et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272 (5266): 1339-1342
• 11 Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67 (4) 1234-1247
• 12 Geng L, Boehmerle W, Maeda Y , et al. Syntaxin 5 regulates the endoplasmic reticulum channel-release properties of polycystin-2. Proc Natl Acad Sci U S A 2008; 105 (41) 15920-15925
• 13 Ward CJ, Hogan MC, Rossetti S , et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002; 30 (3) 259-269
• 14 Al-Bhalal L, Akhtar M. Molecular basis of autosomal recessive polycystic kidney disease (ARPKD). Adv Anat Pathol 2008; 15 (1) 54-58
• 15 Porath B, Gainullin VG, Cornec-Le Gall E , et al. Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet 2016; 98 (6) 1193-1207
• 16 Fedeles SV, Tian X, Gallagher AR , et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet 2011; 43 (7) 639-647
• 17 Janssen MJ, Waanders E, Te Morsche RH , et al. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology 2011; 141 (6) 2056-2063.e2
• 18 Cnossen WR, Drenth JP. Somatic hits in polycystic liver diseases. J Carcinog Mutagen 2013; 19 (1) 141-143
• 19 Janssen MJ, Salomon J, Te Morsche RH, Drenth JP. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS One 2012; 7 (11) e50324
• 20 Pei Y, Watnick T, He N , et al. Somatic PKD2 mutations in individual kidney and liver cysts support a “two-hit” model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999; 10 (7) 1524-1529
• 21 Watnick TJ, Torres VE, Gandolph MA , et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell 1998; 2 (2) 247-251
• 22 Raynaud P, Tate J, Callens C , et al. A classification of ductal plate malformations based on distinct pathogenic mechanisms of biliary dysmorphogenesis. Hepatology 2011; 53 (6) 1959-1966
• 23 Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008; 237 (8) 2007-2012
• 24 Basten SG, Giles RH. Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. Cilia 2013; 2 (1) 6
• 25 Masyuk AI, Masyuk TV, Splinter PL, Huang BQ, Stroope AJ, LaRusso NF. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131 (3) 911-920
• 26 Masyuk AI, Gradilone SA, Banales JM , et al. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am J Physiol Gastrointest Liver Physiol 2008; 295 (4) G725-G734
• 27 Masyuk AI, Huang BQ, Radtke BN , et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304 (11) G1013-G1024
• 28 Masyuk AI, Huang BQ, Ward CJ , et al. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol Gastrointest Liver Physiol 2010; 299 (4) G990-G999
• 29 Gradilone SA, Masyuk AI, Splinter PL , et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc Natl Acad Sci U S A 2007; 104 (48) 19138-19143
• 30 Onori P, Franchitto A, Mancinelli R , et al. Polycystic liver diseases. Dig Liver Dis 2010; 42 (4) 261-271
• 31 Lee SH, Somlo S. Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease. Kidney Res Clin Pract 2014; 33 (2) 73-78
• 32 Fedeles SV, Gallagher AR, Somlo S. Polycystin-1: a master regulator of intersecting cystic pathways. Trends Mol Med 2014; 20 (5) 251-260
• 33 Masyuk TV, Lee SO, Radtke BN , et al. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol 2014; 184 (1) 110-121
• 34 Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49 (1) 160-174
• 35 Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007; 132 (3) 1104-1116
• 36 Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011; 140 (7) 1855-1859 , 1859.e1
• 37 Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE. Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol 2015; 11 (8) 451-464
• 38 Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014; 25 (1) 18-32
• 39 Gradilone SA, Masyuk TV, Huang BQ , et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 2010; 139 (1) 304-14.e2
• 40 Munoz-Garrido P, Marin JJ, Perugorria MJ , et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015; 63 (4) 952-961
• 41 Spirli C, Morell CM, Locatelli L , et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 2012; 56 (6) 2363-2374
• 42 Santos-Laso A, Munoz-Garrido P, Felipe-Agirre M, Bujanda L, Banales JM, Perugorria MJ. New advances in the molecular mechanisms driving biliary fibrosis and emerging molecular targets. Curr Drug Targets 2015; ; PMID: 25915485
• 43 Spirli C, Okolicsanyi S, Fiorotto R , et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 2010; 138 (1) 360-371.e7
• 44 Fabris L, Cadamuro M, Fiorotto R , et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43 (5) 1001-1012
• 45 Brodsky KS, McWilliams RR, Amura CR, Barry NP, Doctor RB. Liver cyst cytokines promote endothelial cell proliferation and development. Exp Biol Med (Maywood) 2009; 234 (10) 1155-1165
• 46 Nichols MT, Gidey E, Matzakos T , et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004; 40 (4) 836-846
• 47 Urribarri AD, Munoz-Garrido P, Perugorria MJ , et al. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut 2014; 63 (10) 1658-1667
• 48 Spirli C, Okolicsanyi S, Fiorotto R , et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 2010; 51 (5) 1778-1788
• 49 Alvaro D, Onori P, Alpini G , et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol 2008; 172 (2) 321-332
• 50 Locatelli L, Cadamuro M, Spirlì C , et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 2016; 63 (3) 965-982
• 51 Spirli C, Locatelli L, Morell CM , et al. Protein kinase A-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology 2013; 58 (5) 1713-1723
• 52 Banales JM, Arenas F, Rodríguez-Ortigosa CM , et al. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology 2006; 43 (2) 266-275
• 53 Banales JM, Prieto J, Medina JF. Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol 2006; 12 (22) 3496-3511
• 54 Banales JM, Masyuk TV, Bogert PS , et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173 (6) 1637-1646
• 55 Afroze S, Meng F, Jensen K , et al. The physiological roles of secretin and its receptor. Ann Transl Med 2013; 1 (3) 29
• 56 Tietz PS, Marinelli RA, Chen XM , et al. Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes. J Biol Chem 2003; 278 (22) 20413-20419
• 57 Everson GT, Emmett M, Brown WR, Redmond P, Thickman D. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 1990; 11 (4) 557-565
• 58 Lee SO, Masyuk T, Splinter P , et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118 (11) 3714-3724
• 59 Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP, Friedman JR. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 2009; 136 (3) 1081-1090
• 60 Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol 2014; 184 (3) 600-608
• 61 Li Y, Zhang X, Polakiewicz RD, Yao TP, Comb MJ. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 2008; 283 (19) 12686-12690
• 62 Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, LaRusso NF. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res 2013; 73 (7) 2259-2270
• 63 Masyuk TV, Radtke BN, Stroope AJ , et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012; 142 (3) 622-633.e4
• 64 Yoshihara D, Kurahashi H, Morita M , et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011; 300 (2) F465-F474
• 65 Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 2007; 293 (1) C419-C428
• 66 Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 2013; 59 (1) 153-159
• 67 Serra AL, Poster D, Kistler AD , et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363 (9) 820-829
• 68 Walz G, Budde K, Mannaa M , et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363 (9) 830-840
• 69 Masyuk TV, Radtke BN, Stroope AJ , et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013; 58 (1) 409-421
• 70 Hogan MC, Masyuk TV, Page LJ , et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21 (6) 1052-1061
• 71 Ruggenenti P, Remuzzi A, Ondei P , et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68 (1) 206-216
• 72 Hogan MC, Masyuk TV, Page L , et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27 (9) 3532-3539
• 73 Temmerman F, Gevers T, Ho TA , et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013; 38 (4) 397-406
• 74 van Keimpema L, Nevens F, Vanslembrouck R , et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137 (5) 1661-8.e1 , 2
• 75 Hogan MC, Masyuk T, Bergstralh E , et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc 2015; 90 (8) 1030-1037
• 76 Chrispijn M, Nevens F, Gevers TJ , et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35 (2) 266-274
• 77 Caroli A, Antiga L, Cafaro M , et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5 (5) 783-789
• 78 Temmerman F, Ho TA, Vanslembrouck R , et al. Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease. Clin Gastroenterol Hepatol 2015; 13 (13) 2353-9.e1
• 79 Larusso NF, Masyuk TV, Hogan MC. Polycystic liver disease: the benefits of targeting cAMP. Clin Gastroenterol Hepatol 2016; 14 (7) 1031-1034
• 80 Gevers TJ, Inthout J, Caroli A , et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013; 145 (2) 357-65.e1 , 2
• 81 Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62 (1, Suppl) S25-S37
• 82 Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ. Bile acids in physiology, pathology and pharmacology. Curr Drug Metab 2015; 17 (1) 4-29
• 83 Alpini G, Baiocchi L, Glaser S , et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 2002; 35 (5) 1041-1052
• 84 Marzioni M, Francis H, Benedetti A , et al. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol 2006; 168 (2) 398-409
• 85 D'Agnolo HMAKW, Takkenberg B, Riaño I , et al. Ursodeoxycholic acid in advanced polycystic liver disease: . a phase 2 multicenter randomized controlled trial. J Hepatol 2016; 65 (3) 601-607
• 86 Iijima T, Hoshino J, Suwabe T , et al. Ursodeoxycholic acid for treatment of enlarged polycystic liver. Ther Apher Dial 2016; 20 (1) 73-78